Big Pharma Eyes Lipoprotein(a) as Next Breakthrough in Heart-Disease Treatment
Major drug makers are testing therapies that lower lipoprotein(a), and upcoming trial data will reveal whether the strategy can transform cardiovascular care.
Several leading pharmaceutical firms are developing medicines that target the blood particle lipoprotein(a), which is linked to heart disease. Results from pending clinical studies are set to show how well this approach works in patients. The push follows heightened biotech activity, illustrated by Dolly Parton's $1 million gift to Vanderbilt University Medical Center for vaccine research. Industry observers are watching the data to gauge the potential of this new drug class.
Why it matters
New lipoprotein(a) drugs could significantly improve outcomes for millions with heart disease.
In this story
